KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Capital Expenditures (2018 - 2025)

Moderna (MRNA) has disclosed Capital Expenditures for 8 consecutive years, with $39.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 105.26% to $39.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $192.0 million, a 97.94% increase, with the full-year FY2025 number at $192.0 million, up 97.94% from a year prior.
  • Capital Expenditures was $39.0 million for Q4 2025 at Moderna, down from $106.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $559.0 million in Q4 2023 to a low of -$300.0 million in Q3 2024.
  • A 5-year average of $67.6 million and a median of $97.5 million in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 1091.67% in 2021, then plummeted 323.6% in 2023.
  • Moderna's Capital Expenditures stood at $120.0 million in 2021, then plummeted by 296.67% to -$236.0 million in 2022, then soared by 336.86% to $559.0 million in 2023, then plummeted by 96.6% to $19.0 million in 2024, then skyrocketed by 105.26% to $39.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Capital Expenditures are $39.0 million (Q4 2025), $106.0 million (Q3 2025), and -$70.0 million (Q2 2025).